
Organogenesis Holdings (ORGO) Stock Forecast & Price Target
Organogenesis Holdings (ORGO) Analyst Ratings
Bulls say
Organogenesis Holdings Inc., a company specializing in regenerative medicine, is well-positioned for growth due to an anticipated improvement in valuation as solid financial results are expected amidst current market dynamics. The final reimbursement rate for the company’s products has increased slightly to $127.28/cm² for CY2026, which suggests an upward trend in operational profitability over time. Additionally, the company is expected to capture a greater market share in a consolidating industry, with shares trading significantly below its peer set, indicating substantial potential for future gains.
Bears say
Organogenesis Holdings Inc. faces significant challenges that contribute to a negative outlook on its stock. Key concerns include the potential for lower-than-expected growth in the PuraPly product line, pricing pressures from Medicare Part B on amniotic products, and the increased efficiency of competitors that could hinder market share gains. Additionally, uncertainties surrounding clinical outcomes, lower uptake of new products, and a possible reduction in sales force efficiencies could further undermine the company's financial performance moving forward.
This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.
Organogenesis Holdings (ORGO) Analyst Forecast & Price Prediction
Start investing in Organogenesis Holdings (ORGO)
Order type
Buy in
Order amount
Est. shares
0 shares